RBC Capital analyst Daniel Busby maintained an Outperform rating on Jazz Pharmaceuticals plc (NASDAQ: JAZZ) on July 23, increasing the price target to $216 per share from $190 previously, citing the FDA-approved Rylaze for acute lymphoblastic leukemia and lymphoblastic lymphoma treatment as a potential growth driver for the company.